A retrospective study of microscopic polyangiitis patients presenting with pulmonary fibrosis in China

Hui Huang, Yan Xun Wang, Chun Guo Jiang

  • 1Department of Respiratory Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, #1 Shuaifuyuan Street, Beijing, Dongcheng District 100730, China. xuzj@hotmail.com.

BMC Pulmonary Medicine
|January 29, 2014
PubMed
Abstract

Insights

Microscopic polyangiitis (MPA) can present as pulmonary fibrosis, often in older females with delayed ANCA positivity. This condition has a poor prognosis, indicating a need for novel therapeutic strategies.

Area of Science:

  • Rheumatology
  • Pulmonology
  • Internal Medicine

Background:

  • Pulmonary involvement is common in microscopic polyangiitis (MPA).
  • While alveolar hemorrhage is typical, pulmonary fibrosis is an emerging manifestation.
  • Pulmonary fibrosis can precede, coincide with, or follow MPA diagnosis.

Purpose of the Study:

  • To characterize the clinical features and prognosis of MPA patients presenting with pulmonary fibrosis.
  • To identify demographic and clinical factors associated with this MPA presentation.

Main Methods:

  • Retrospective analysis of 19 MPA patients with pulmonary fibrosis.
  • Data collected from Peking Union Medical College Hospital (1990-2012).
  • Review of clinical manifestations, laboratory findings, HRCT, ANCA status, and treatment outcomes.

Main Results:

  • 19 of 67 MPA cases presented with pulmonary fibrosis (median age 63.6, 11 females).
  • Common symptoms included fever, cough, dyspnea, and velcro rales; 63% had weight loss and kidney involvement.
  • All patients were myeloperoxidase-ANCA positive; 35% had delayed ANCA positivity. Usual interstitial pneumonia pattern seen on HRCT.
  • Corticosteroids and cyclophosphamide led to improvement in 12 patients; 6 patients died.

Conclusions:

  • MPA patients with pulmonary fibrosis are often older, female, and present with extrapulmonic involvement.
  • Delayed ANCA positivity is common in this cohort.
  • The prognosis for MPA with pulmonary fibrosis appears poor, highlighting the need for new treatment approaches.

Related Concept Videos

Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
161
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
475
Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
891
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
547
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies01:27

Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies

Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
3.2K
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
998